Fluorine-18-DCFPyL - Progenics Pharmaceuticals

Drug Profile

Fluorine-18-DCFPyL - Progenics Pharmaceuticals

Alternative Names: [18F]DCFPyL; DCFPyL-18F; PyL™

Latest Information Update: 18 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johns Hopkins University School of Medicine
  • Developer National Cancer Institute (USA); Northwestern University; Progenics Pharmaceuticals; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Wisconsin-Madison
  • Class Antineoplastics; Imaging agents; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Prostate cancer
  • Phase II Gynaecological cancer
  • Phase I Neurilemmoma

Most Recent Events

  • 18 Jul 2018 Fluorine-18-DCFPyL is still in phase I trials for Neurilemmoma (Diagnosis) in USA (IV) (NCT03542773)
  • 28 Jun 2018 No recent reports of development identified for phase-I development in Neurilemmoma(Diagnosis) in USA (IV, Injection)
  • 26 Jun 2018 Progenics Pharmaceuticals completes enrolment in its phase II/III OSPREY trial for Prostate cancer in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top